Barclays Trims Danaher (NYSE:DHR) Target Price to $275.00

Danaher (NYSE:DHR) had its price target decreased by Barclays from $285.00 to $275.00 in a research note released on Wednesday, Benzinga reports. Barclays currently has an equal weight rating on the conglomerate’s stock.

Several other analysts have also issued reports on DHR. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 target price on shares of Danaher in a research report on Friday, September 6th. Wells Fargo & Company began coverage on Danaher in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price objective on the stock. Evercore ISI increased their target price on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Robert W. Baird lowered their price target on Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research note on Wednesday. Finally, Stephens began coverage on Danaher in a research note on Tuesday, October 1st. They issued an “overweight” rating and a $315.00 price objective for the company. Seven analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and an average target price of $287.28.

Danaher Trading Down 1.1 %

DHR stock opened at $245.39 on Wednesday. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. Danaher has a 52-week low of $182.09 and a 52-week high of $281.70. The company’s 50-day simple moving average is $269.52 and its 200-day simple moving average is $260.42. The firm has a market cap of $181.76 billion, a P/E ratio of 41.59, a PEG ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the previous year, the business earned $2.02 earnings per share. The business’s revenue was up 3.1% compared to the same quarter last year. As a group, equities analysts forecast that Danaher will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s dividend payout ratio is presently 18.31%.

Insiders Place Their Bets

In other news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Danaher news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at $27,435,240. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,059 shares of company stock valued at $8,400,897 over the last quarter. 11.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Danaher

Several institutional investors and hedge funds have recently modified their holdings of DHR. Tsfg LLC increased its stake in Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 88 shares during the period. CarsonAllaria Wealth Management Ltd. acquired a new position in shares of Danaher in the second quarter valued at approximately $25,000. nVerses Capital LLC purchased a new stake in Danaher during the 2nd quarter worth approximately $25,000. Redmont Wealth Advisors LLC acquired a new stake in Danaher during the 1st quarter worth approximately $30,000. Finally, MFA Wealth Advisors LLC purchased a new position in Danaher in the 2nd quarter valued at approximately $51,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.